利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

34 条记录 (耗时 0.024 秒)

    Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions
    11.
    发明申请
    Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions 有权
    包含CB1大麻素受体拮抗剂和用于治疗肥胖症和相关病症的钾通道开放剂的药物组合物

    公开(公告)号：US20060128673A1

    公开(公告)日：2006-06-15

    申请号：US11257056

    申请日：2005-10-25

    申请人： Michael Firnges ,  Peter-Colin Gregory ,  Jochen Antel ,  Josephus Maria Lange ,  Harald Waldeck

    发明人： Michael Firnges ,  Peter-Colin Gregory ,  Jochen Antel ,  Josephus Maria Lange ,  Harald Waldeck

    IPC分类号： A61K31/655 ,  A61K31/4439 ,  A61K31/4152 ,  A61K31/454 ,  A61K31/5377

    CPC分类号： A61K31/00 ,  A61K31/40 ,  A61K31/415 ,  A61K31/4152 ,  A61K31/427 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/5377 ,  A61K31/54 ,  A61K31/655 ,  A61K45/06 ,  G01N33/6872 ,  G01N33/948 ,  G01N2500/00 ,  G01N2800/042 ,  G01N2800/044 ,  A61K2300/00

    摘要： Described is a novel combination therapy for diabetes mellitus type I and/or for obesity and its concomitant and/or secondary diseases or conditions, in particular the metabolic syndrome and/or syndrome X, and/or diabetes mellitus type II, by administering a combination of at least one KATP channel opener as a first active agent and at least one CB1 cannabinoid receptor antagonist as a second active agent. The invention is further directed to such novel combination therapy wherein a dually acting compound with combined KATP channel opening and CB1 antagonistic properties is used. The invention also relates to novel pharmaceutical compositions comprising KATP channel openers and CB1 antagonists and the use of said pharmaceutical compositions in the treatment, delayed progression, delayed onset of and/or inhibition of diabetes mellitus type 1, and the prophylaxis and treatment, of obesity as well as the prophylaxis, treatment, delayed onset and/or inhbition of its concomitant and/or secondary diseases or conditions, in particular the metabolic syndrome and/or syndrome X, and/or diabetes mellitus type II, in mammals and humans. The invention is further directed to such novel pharmaceutical compositions comprising a dually acting compound with combined KATP channel opening and CB1 antagonistic properties.

    摘要翻译： 描述了通过施用组合来描述I型糖尿病和/或用于肥胖及其伴随和/或继发疾病或病症，特别是代谢综合征和/或综合征X和/或II型糖尿病的新型联合治疗 的至少一个K ATP通道开放剂作为第一活性剂和至少一种作为第二活性剂的CB 1大麻素受体拮抗剂。 本发明进一步涉及这样的新型组合疗法，其中使用具有组合的K ATP通道开口和CB 1拮抗性质的双作用化合物。 本发明还涉及包含K ATP通道开放剂和CB 1拮抗剂的新型药物组合物，以及所述药物组合物在治疗，延迟进展，延迟发作和/ 或抑制1型糖尿病，以及预防和治疗肥胖症以及其并发症和/或继发性疾病或病症，特别是代谢综合征和/或综合征的预防，治疗，延迟发作和/或吸收 X和/或II型糖尿病。 本发明进一步涉及这样的新型药物组合物，其包含具有组合的K ATP通道开口和CB 1拮抗性质的双作用化合物。

    Method of preparing pharmaceutical compositions
    18.
    发明授权
    Method of preparing pharmaceutical compositions 有权
    制备药物组合物的方法

    公开(公告)号：US07282325B2

    公开(公告)日：2007-10-16

    申请号：US10785043

    申请日：2004-02-25

    申请人： Johannes Hebebrand ,  Jochen Antel ,  Ulf Preuschoff ,  Samuel David ,  Holger Sann ,  Michael Weske

    发明人： Johannes Hebebrand ,  Jochen Antel ,  Ulf Preuschoff ,  Samuel David ,  Holger Sann ,  Michael Weske

    IPC分类号： C12Q1/00

    CPC分类号： A61K31/34 ,  C12Q1/527 ,  G01N33/6893 ,  G01N2800/044

    摘要： A method for the discovery of compounds suitable for the treatment and/or prophylaxis of obesity, in which the ability of the test compounds to inhibit de novo lipogenesis in mammals and/or man is determined. The use of compounds which are capable of inhibiting de novo lipogenesis in mammals, and which are substantially free of effects directed towards the CNS, for the preparation of pharmaceutical compositions for the treatment and/or prophylaxis of obesity, as well as for the treatment and/or inhibition of obesity, are also described.

    摘要翻译： 发现适用于治疗和/或预防肥胖症的化合物的方法，其中测定化合物在哺乳动物和/或人中抑制新生脂肪生成的能力。 使用能够在哺乳动物中抑制从头脂肪生成并且基本上没有针对CNS的作用的化合物用于制备用于治疗和/或预防肥胖症的药物组合物，以及用于治疗和/ /或抑制肥胖。